摘要
目的:探讨孟鲁司特与布地奈德气雾剂治疗小儿咳嗽变异性哮喘(CVA)的临床疗效。方法:69例CVA患儿随机分成三组,三组均以口服特布他林为基础治疗,在此基础上分别加用酮替芬(A组)、孟鲁司特(B组)和布地奈德气雾剂(C组),治疗后比较三组疗效。结果:临床缓解所需时间A组为(12.4±4.3)d,B组为(6.2±3.9)d,C组为(7.3±4.1)d,A组与B组、C组比较差异均有统计学意义(P<0.01),B组与C组比较差异无统计学意义(P>0.05)。CVA复发率A组(34.6%)高于B组(9.5%)和C组(9.1%),差异有统计学意义(P均<0.05),B组与C组比较差异无统计学意义(P>0.05)。结论:盂鲁司特与布地奈德气雾剂在控制CVA临床症状方面均有较好疗效,二者对预防CVA复发疗效相当。
Objective：To explore the curative effect of the montelukast and budesonide aerosol on children with cough variant asthma （CVA）. Methods ：The 69 cases of CVA were randomly divided into three groups, ketotifen group （group A）, montelukast group （group B）, budesonide aerosol group （group C ）. All of these groups were also basically treated with oral terbutaline. Then the curative effects of the three groups were compared after treatment. Results ：The time of clinical relieving of group A was longer than that of group B and group C （P 〈 0.01 ）, the difference was significant. There was no significant difference between group B and group C （P 〉 0.05 ）. The CVA recurrence rate of group A was higher than that of group B and group C （ P 〈 0.05） with a significant difference, but group B and group C didn＇t have any significant difference. Conclusions： Both montelukast and budesonide aerosol have great therapeutic effects, while they have the same curative effect on preventing the recurrence of CVA.
出处
《儿科药学杂志》
CAS
2008年第3期39-40,共2页
Journal of Pediatric Pharmacy
作者简介
方薇（1964-），大学本科，副主任医师，主要从事小儿呼吸系统疾病研究，E-msil．FangWei1234．ok@163．com。
